Form 4: Arcus Biosciences CEO Gifts 35,000 Shares

Arcus Biosciences CEO Terry J. Rosen reported a charitable gift of 35,000 shares of common stock, executed under a Rule 10b5-1 plan.

Summary

• Terry J. Rosen, Chief Executive Officer and Director of Arcus Biosciences, Inc. (RCUS), disposed of 35,000 shares of common stock.
• The transaction, dated January 8, 2026, was a charitable gift.
• The disposition was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following this transaction, Mr. Rosen directly beneficially owns 2,157,409 shares of common stock, which includes unvested RSU grants.

Sentiment

Score: 5

Explanation: A routine insider transaction (charitable gift) under a pre-planned Rule 10b5-1 plan, which is generally neutral for stock sentiment as it does not reflect a change in management's view of the company's prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, demonstrating adherence to pre-planned trading policies and enhancing transparency.

Negatives

• A reduction in direct beneficial ownership by a key executive, although for charitable purposes.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the pre-planned nature under Rule 10b5-1(c) suggests a non-eventful, transparent transaction, unlikely to impact sentiment significantly.

Key Dates

Recommendation

The filing reports a routine, pre-planned charitable gift of shares by the CEO, which does not provide new material information to alter an investment thesis. It's a neutral event for the stock's valuation and does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

Arcus Biosciences, RCUS, Form 4, insider transaction, stock disposition, CEO, charitable gift, Rule 10b5-1